Subgroup analysis showed that patients with larger tumor, extrahepatic metastases, PVTT type I/II, and higher alpha-fetoprotein (AFP) level appeared to benefit more from TACE plus lenvatinib (Ding et al., 2021). This evidence concerns the gene AFP and neoplasm.